From molecular sequence to analytical verification.
An editorial introduction to the scientific terminology, analytical concepts, evidence framework and peer-reviewed literature that structure responsible peptide research.
Foundational vocabulary.
- PeptideShort chain of amino acids linked by peptide bonds.
- SequenceThe defined order of amino acids that gives a peptide its identity.
- SynthesisChemical or biological process used to assemble a defined peptide.
- PurityProportion of the target peptide relative to impurities in a sample.
- IdentityConfirmation that a sample corresponds to the declared peptide.
- Analytical standardA characterized reference material used to verify identity and purity.
- In vitroResearch performed outside a living organism, e.g. in cell culture.
- PharmacokineticsHow a compound is absorbed, distributed, metabolized and eliminated.
- Half-lifeTime required for a concentration to decrease by half.
- Evidence levelA classification describing the maturity and rigour of available data.
Evidence levels.
Evidence levels describe research maturity. They do not constitute a recommendation or an endorsement of human use.
Peptide science does not stop at the chromatogram.
Analytical identity, formulation robustness and sterile manufacturing are not separate disciplines. A peptide can pass identity and purity on the bulk CoA and still fail as a finished injectable: counterion content, residual moisture, endotoxin burden, in-solution hold-time degradation, filter adsorption, and freeze-drying behaviour all sit between the molecule and a usable vial.
The lyophilized bulk powder is redissolved, formulated with cryo- and lyoprotectants, sterile-filtered, aseptically filled and re-lyophilized inside the final vial. Each step has its own failure modes and its own regulatory anchors — EU GMP Annex 1, ICH Q8, ICH Q5C, and FDA lyophilization guidance — and each one is a place where the science is either honoured or lost.
- 01Incoming API control beyond a CoA
- 02Formulation development & excipient rationale
- 03Sterile filtration & aseptic fill
- 04Lyophilization in the final vial
- 05"Second lyophilization" vs "secondary drying"
- 06Finished-product testing & stability
A curated index of peer-reviewed peptide research.
The references below are independently published peer-reviewed sources used to inform our editorial framework. They are listed for transparency and scientific orientation — not as endorsements of any compound, product or human use.
- 01 / 12TherapeuticsLevel 6 review
Therapeutic peptides: current applications and future directions.
Wang L, Wang N, Zhang W, et al.
Signal Transduction and Targeted Therapy · 2022
Open-access synthesis of clinically used peptide therapeutics across metabolic, oncologic and cardiovascular indications.
TherapeuticsLevel 6 reviewdoi:10.1038/s41392-022-00904-4Open source → - 02 / 12DiscoveryLevel 6 review
Trends in peptide drug discovery.
Muttenthaler M, King GF, Adams DJ, Alewood PF.
Nature Reviews Drug Discovery · 2021
A landscape review of approved peptide drugs, modern discovery platforms, and structural strategies that improve drug-likeness.
DiscoveryLevel 6 reviewdoi:10.1038/s41573-020-00135-8Open source → - 03 / 12StabilityLevel 6 review
Freeze-drying of pharmaceutical and biopharmaceutical products: process design and optimization.
Pisano R, Fissore D, Barresi AA.
Pharmaceutics · 2020
Comprehensive review of lyophilization cycle design — freezing, primary and secondary drying — and the impact of formulation and process parameters on cake structure and residual moisture.
StabilityLevel 6 reviewdoi:10.3390/pharmaceutics12121063Open source → - 04 / 12TherapeuticsLevel 6 review
Therapeutic peptides: historical perspectives, current development trends and future directions.
Lau JL, Dunn MK.
Bioorganic & Medicinal Chemistry · 2018
Historical and structural analysis of FDA-approved peptide drugs and the chemical strategies driving their evolution.
TherapeuticsLevel 6 reviewdoi:10.1016/j.bmc.2017.06.052Open source → - 05 / 12DiscoveryLevel 6 review
The current state of peptide drug discovery: back to the future?
Henninot A, Collins JC, Nuss JM.
Journal of Medicinal Chemistry · 2018
Critical review of macrocyclic and constrained peptide platforms and their re-emergence in modern medicinal chemistry.
DiscoveryLevel 6 reviewdoi:10.1021/acs.jmedchem.7b00318Open source → - 06 / 12DiscoveryLevel 6 method review
Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences.
Behrendt R, White P, Offer J.
Journal of Peptide Science · 2016
Authoritative methodological review of Fmoc-SPPS, common side reactions and strategies for sequences prone to aggregation.
DiscoveryLevel 6 method reviewdoi:10.1002/psc.2836Open source → - 07 / 12DeliveryLevel 6 review
Peptide therapeutics: current status and future directions.
Fosgerau K, Hoffmann T.
Drug Discovery Today · 2015
Overview of delivery, half-life extension and formulation challenges shaping peptide pipeline strategy.
DeliveryLevel 6 reviewdoi:10.1016/j.drudis.2014.10.003Open source → - 08 / 12StabilityLevel 2 in vitro
Stability of peptide drugs in the colon and other physiological environments: a kinetic perspective.
Wang J, Yadav V, Smart AL, Tajiri S, Basit AW.
Molecular Pharmaceutics · 2015
Kinetic in vitro study quantifying proteolytic stability of model peptides across simulated physiological environments.
StabilityLevel 2 in vitrodoi:10.1021/mp500809fOpen source → - 09 / 12AnalyticalLevel 6 review
Related impurities in peptide medicines.
D'Hondt M, Bracke N, Taevernier L, et al.
Journal of Pharmaceutical and Biomedical Analysis · 2014
Classification of synthesis-, degradation- and formulation-related impurities in peptide drug products, with analytical control strategies.
AnalyticalLevel 6 reviewdoi:10.1016/j.jpba.2014.06.012Open source → - 10 / 12DeliveryLevel 6 review
Excipients for protein drugs.
Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB.
Advanced Drug Delivery Reviews · 2011
Mechanistic review of buffer systems, sugars, surfactants and tonicity agents used in parenteral peptide and protein formulations, with rationale for selection.
DeliveryLevel 6 reviewdoi:10.1016/j.addr.2011.06.015Open source → - 11 / 12StabilityLevel 6 review
Stability of protein pharmaceuticals: an update.
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS.
Pharmaceutical Research · 2010
Updated review of degradation pathways — deamidation, oxidation, aggregation — and stabilization strategies for peptide and protein formulations.
StabilityLevel 6 reviewdoi:10.1007/s11095-009-0045-6Open source → - 12 / 12StabilityLevel 6 method review
Rational design of stable lyophilized protein formulations: theory and practice.
Carpenter JF, Pikal MJ, Chang BS, Randolph TW.
Pharmaceutical Research · 1997
Foundational treatment of cryo- and lyoprotection, glass-transition behaviour, and the formulation principles still used today for peptide and protein freeze-drying.
StabilityLevel 6 method reviewdoi:10.1023/A:1012180707283Open source →
All references link directly to the publisher record via DOI. Citations are reproduced for educational and editorial purposes; copyright remains with the respective publishers and authors. No content on this page is a substitute for qualified clinical, legal or regulatory consultation, and no compound described in the cited literature is offered by VisaVault Lifescience for human use.